Nucala 100 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FMEB4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,591
Award facts
- Contract value 100% obligated
- $11,591.04 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $11,591.04 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of NUCALA 100 mg/mL syringes. The delivery order was issued without set-aside designation on December 11, 2025, with an ultimate completion date of December 12, 2025. This award represents one of numerous delivery orders issued to DMS Pharmaceutical Group under its single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide comprehensive pharmaceutical supply solutions to Department of Defense military healthcare facilities worldwide.
DMS Pharmaceutical Group's IDC under PPV-G GEN V was established on November 13, 2025, with a ceiling value of $499,999,999 and extends through December 31, 2036, encompassing a 30-month base period and three 30-month option periods. The contract authorizes DLA to issue firm fixed-price delivery orders across a broad range of pharmaceuticals including branded and generic prescription medications, biologics, vaccines, and medical consumables to support military medical operations globally. The vendor's established performance across multiple therapeutic categories and product lines, combined with its small business status and continuous federal contracting activity, positions it as a critical supplier within the Department of Defense pharmaceutical supply chain.
Quick answers
Who was awarded contract SPE2DR26FMEB4?
SPE2DR26FMEB4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 11, 2025.
How much is contract SPE2DR26FMEB4 worth?
The government has obligated $11,591 on SPE2DR26FMEB4.
Is contract SPE2DR26FMEB4 an order under another contract?
Yes. SPE2DR26FMEB4 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMEB4 competed?
The extent of competition for SPE2DR26FMEB4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award